CALM1 and DAPK1 |
calmodulin 1 (phosphorylase kinase, delta) |
death-associated protein kinase 1 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Signaling by Wnt
- Platelet degranulation
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- Glucose metabolism
- DAP12 signaling
- Synthesis of IP3 and IP4 in the cytosol
- Myoclonic epilepsy of Lafora
- Response to elevated platelet cytosolic Ca2+
- Glycogen storage diseases
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Activation of Ca-permeable Kainate Receptor
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ionotropic activity of Kainate Receptors
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- Glycogen breakdown (glycogenolysis)
- Opioid Signalling
- Activation of Kainate Receptors upon glutamate binding
- Diseases associated with visual transduction
- Inositol phosphate metabolism
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by VEGF
- CREB phosphorylation through the activation of CaMKK
- Downstream signal transduction
- Calmodulin induced events
- CREB phosphorylation through the activation of CaMKII
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Metabolism of carbohydrates
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Organelle biogenesis and maintenance
- Cam-PDE 1 activation
- Translocation of GLUT4 to the plasma membrane
- VEGFA-VEGFR2 Pathway
- DAG and IP3 signaling
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- Metabolism of nitric oxide
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated vascular permeability
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- The phototransduction cascade
- Downstream signaling of activated FGFR
- DARPP-32 events
- eNOS activation and regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Post NMDA receptor activation events
- Signalling by NGF
- PLC beta mediated events
- Smooth Muscle Contraction
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- beta-catenin independent WNT signaling
- Signaling by FGFR
- eNOS activation
- Cam-PDE 1 activation
- Ca2+ pathway
- Visual phototransduction
- Activation of CaMK IV
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- Programmed Cell Death
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
|
- 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
- Phosphoaminophosphonic Acid-Adenylate Ester
- 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
|
|
|
CALM2 and EGFR |
calmodulin 2 (phosphorylase kinase, delta) |
epidermal growth factor receptor |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Signaling by Wnt
- Platelet degranulation
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- Glucose metabolism
- DAP12 signaling
- Synthesis of IP3 and IP4 in the cytosol
- Myoclonic epilepsy of Lafora
- Response to elevated platelet cytosolic Ca2+
- Glycogen storage diseases
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Activation of Ca-permeable Kainate Receptor
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ionotropic activity of Kainate Receptors
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- Glycogen breakdown (glycogenolysis)
- Opioid Signalling
- Activation of Kainate Receptors upon glutamate binding
- Diseases associated with visual transduction
- Inositol phosphate metabolism
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by VEGF
- CREB phosphorylation through the activation of CaMKK
- Downstream signal transduction
- Calmodulin induced events
- CREB phosphorylation through the activation of CaMKII
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Metabolism of carbohydrates
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Organelle biogenesis and maintenance
- Cam-PDE 1 activation
- Translocation of GLUT4 to the plasma membrane
- VEGFA-VEGFR2 Pathway
- DAG and IP3 signaling
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- Metabolism of nitric oxide
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated vascular permeability
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- The phototransduction cascade
- Downstream signaling of activated FGFR
- DARPP-32 events
- eNOS activation and regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Post NMDA receptor activation events
- Signalling by NGF
- PLC beta mediated events
- Smooth Muscle Contraction
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- beta-catenin independent WNT signaling
- Signaling by FGFR
- eNOS activation
- Cam-PDE 1 activation
- Ca2+ pathway
- Visual phototransduction
- Activation of CaMK IV
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
CALM2 and CCND2 |
calmodulin 2 (phosphorylase kinase, delta) |
cyclin D2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Signaling by Wnt
- Platelet degranulation
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- Glucose metabolism
- DAP12 signaling
- Synthesis of IP3 and IP4 in the cytosol
- Myoclonic epilepsy of Lafora
- Response to elevated platelet cytosolic Ca2+
- Glycogen storage diseases
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Activation of Ca-permeable Kainate Receptor
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ionotropic activity of Kainate Receptors
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- Glycogen breakdown (glycogenolysis)
- Opioid Signalling
- Activation of Kainate Receptors upon glutamate binding
- Diseases associated with visual transduction
- Inositol phosphate metabolism
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by VEGF
- CREB phosphorylation through the activation of CaMKK
- Downstream signal transduction
- Calmodulin induced events
- CREB phosphorylation through the activation of CaMKII
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Metabolism of carbohydrates
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Organelle biogenesis and maintenance
- Cam-PDE 1 activation
- Translocation of GLUT4 to the plasma membrane
- VEGFA-VEGFR2 Pathway
- DAG and IP3 signaling
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- Metabolism of nitric oxide
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated vascular permeability
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- The phototransduction cascade
- Downstream signaling of activated FGFR
- DARPP-32 events
- eNOS activation and regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Post NMDA receptor activation events
- Signalling by NGF
- PLC beta mediated events
- Smooth Muscle Contraction
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- beta-catenin independent WNT signaling
- Signaling by FGFR
- eNOS activation
- Cam-PDE 1 activation
- Ca2+ pathway
- Visual phototransduction
- Activation of CaMK IV
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- Cyclin D associated events in G1
- G1 Phase
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
|
|
|
|
|
CALM3 and EGFR |
calmodulin 3 (phosphorylase kinase, delta) |
epidermal growth factor receptor |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Signaling by Wnt
- Platelet degranulation
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- Glucose metabolism
- DAP12 signaling
- Synthesis of IP3 and IP4 in the cytosol
- Myoclonic epilepsy of Lafora
- Response to elevated platelet cytosolic Ca2+
- Glycogen storage diseases
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Activation of Ca-permeable Kainate Receptor
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ionotropic activity of Kainate Receptors
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- Glycogen breakdown (glycogenolysis)
- Opioid Signalling
- Activation of Kainate Receptors upon glutamate binding
- Diseases associated with visual transduction
- Inositol phosphate metabolism
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by VEGF
- CREB phosphorylation through the activation of CaMKK
- Downstream signal transduction
- Calmodulin induced events
- CREB phosphorylation through the activation of CaMKII
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Metabolism of carbohydrates
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Organelle biogenesis and maintenance
- Cam-PDE 1 activation
- Translocation of GLUT4 to the plasma membrane
- VEGFA-VEGFR2 Pathway
- DAG and IP3 signaling
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- Metabolism of nitric oxide
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated vascular permeability
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- The phototransduction cascade
- Downstream signaling of activated FGFR
- DARPP-32 events
- eNOS activation and regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Post NMDA receptor activation events
- Signalling by NGF
- PLC beta mediated events
- Smooth Muscle Contraction
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- beta-catenin independent WNT signaling
- Signaling by FGFR
- eNOS activation
- Cam-PDE 1 activation
- Ca2+ pathway
- Visual phototransduction
- Activation of CaMK IV
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
- Dibucaine
- Nicardipine
- Fluphenazine
- Isoflurane
- Trifluoperazine
- Loperamide
- Perphenazine
- Phenoxybenzamine
- Felodipine
- Melatonin
- Promethazine
- Pimozide
- Nifedipine
- Bepridil
- Calcium
- Aprindine
- 3\'\'-(Beta-Chloroethyl)-2\'\',4\'\'-Dioxo-3, 5\'\'-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine
- 2-Methyl-2-Propanol
- N-Trimethyllysine
- N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
- Prenylamine
- Flunarizine
- (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
- MYRISTIC ACID
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
CALM3 and CCND2 |
calmodulin 3 (phosphorylase kinase, delta) |
cyclin D2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Signaling by Wnt
- Platelet degranulation
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- Glucose metabolism
- DAP12 signaling
- Synthesis of IP3 and IP4 in the cytosol
- Myoclonic epilepsy of Lafora
- Response to elevated platelet cytosolic Ca2+
- Glycogen storage diseases
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Activation of Ca-permeable Kainate Receptor
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ionotropic activity of Kainate Receptors
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- Glycogen breakdown (glycogenolysis)
- Opioid Signalling
- Activation of Kainate Receptors upon glutamate binding
- Diseases associated with visual transduction
- Inositol phosphate metabolism
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by VEGF
- CREB phosphorylation through the activation of CaMKK
- Downstream signal transduction
- Calmodulin induced events
- CREB phosphorylation through the activation of CaMKII
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Metabolism of carbohydrates
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Organelle biogenesis and maintenance
- Cam-PDE 1 activation
- Translocation of GLUT4 to the plasma membrane
- VEGFA-VEGFR2 Pathway
- DAG and IP3 signaling
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- Metabolism of nitric oxide
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated vascular permeability
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- The phototransduction cascade
- Downstream signaling of activated FGFR
- DARPP-32 events
- eNOS activation and regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Post NMDA receptor activation events
- Signalling by NGF
- PLC beta mediated events
- Smooth Muscle Contraction
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- beta-catenin independent WNT signaling
- Signaling by FGFR
- eNOS activation
- Cam-PDE 1 activation
- Ca2+ pathway
- Visual phototransduction
- Activation of CaMK IV
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- Cyclin D associated events in G1
- G1 Phase
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
|
- Dibucaine
- Nicardipine
- Fluphenazine
- Isoflurane
- Trifluoperazine
- Loperamide
- Perphenazine
- Phenoxybenzamine
- Felodipine
- Melatonin
- Promethazine
- Pimozide
- Nifedipine
- Bepridil
- Calcium
- Aprindine
- 3\'\'-(Beta-Chloroethyl)-2\'\',4\'\'-Dioxo-3, 5\'\'-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine
- 2-Methyl-2-Propanol
- N-Trimethyllysine
- N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
- Prenylamine
- Flunarizine
- (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
- MYRISTIC ACID
|
|
|
|
CASP3 and CDKN1A |
caspase 3, apoptosis-related cysteine peptidase |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
- SMAC binds to IAPs
- SMAC-mediated dissociation of IAP:caspase complexes
- SMAC-mediated apoptotic response
- Cytochrome c-mediated apoptotic response
- Caspase-mediated cleavage of cytoskeletal proteins
- Degradation of the extracellular matrix
- Role of DCC in regulating apoptosis
- Activation of caspases through apoptosome-mediated cleavage
- Activation of DNA fragmentation factor
- Apoptotic factor-mediated response
- Programmed Cell Death
- Intrinsic Pathway for Apoptosis
- Signalling by NGF
- Apoptotic cleavage of cellular proteins
- Cell death signalling via NRAGE, NRIF and NADE
- Apoptotic execution phase
- p75 NTR receptor-mediated signalling
- Stimulation of the cell death response by PAK-2p34
- Apoptotic cleavage of cell adhesion proteins
- Signaling by Hippo
- Apoptosis induced DNA fragmentation
- Extrinsic Pathway
- NADE modulates death signalling
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- Cyclin E associated events during G1/S transition
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- G1/S Transition
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Signaling by PDGF
- DAP12 interactions
- DNA Damage/Telomere Stress Induced Senescence
- GAB1 signalosome
- Senescence-Associated Secretory Phenotype (SASP)
- S Phase
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- SCF(Skp2)-mediated degradation of p27/p21
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Adaptive Immune System
- PIP3 activates AKT signaling
- Orc1 removal from chromatin
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Transcriptional activation of p53 responsive genes
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Transcriptional activation of cell cycle inhibitor p21
- Signalling by NGF
- Synthesis of DNA
- G1 Phase
- Regulation of DNA replication
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- Signaling by FGFR
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Cell Cycle Checkpoints
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N\'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
|
|
|
CASP9 and DCC |
caspase 9, apoptosis-related cysteine peptidase |
DCC netrin 1 receptor |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- SMAC binds to IAPs
- SMAC-mediated dissociation of IAP:caspase complexes
- Cytochrome c-mediated apoptotic response
- SMAC-mediated apoptotic response
- Signaling by EGFRvIII in Cancer
- AKT phosphorylates targets in the cytosol
- Role of DCC in regulating apoptosis
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Activation of caspases through apoptosome-mediated cleavage
- Formation of apoptosome
- PI3K/AKT activation
- PI-3K cascade
- Apoptotic factor-mediated response
- NOD1/2 Signaling Pathway
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Programmed Cell Death
- Innate Immune System
- Intrinsic Pathway for Apoptosis
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Extrinsic Pathway
- Adaptive Immune System
|
- DSCAM interactions
- Axon guidance
- Role of second messengers in netrin-1 signaling
- DCC mediated attractive signaling
- Programmed Cell Death
- Netrin mediated repulsion signals
- Netrin-1 signaling
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
|
|
|
|
CAV1 and ERBB2 |
caveolin 1, caveolae protein, 22kDa |
erb-b2 receptor tyrosine kinase 2 |
- Metabolism of lipids and lipoproteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Lipid digestion, mobilization, and transport
- Signaling by Wnt
- Basigin interactions
- VEGFA-VEGFR2 Pathway
- Cell surface interactions at the vascular wall
- eNOS activation
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Metabolism of nitric oxide
- Signaling by VEGF
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- NOSTRIN mediated eNOS trafficking
- VEGFR2 mediated vascular permeability
- XAV939 inhibits tankyrase, stabilizing AXIN
- eNOS activation and regulation
- Signaling by WNT in cancer
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Axon guidance
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Sema4D in semaphorin signaling
- Sema4D induced cell migration and growth-cone collapse
- Innate Immune System
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
|
- Trastuzumab
- Lapatinib
- ado-trastuzumab emtansine
- Pertuzumab
- Afatinib
|
|
|
CAV1 and PTEN |
caveolin 1, caveolae protein, 22kDa |
phosphatase and tensin homolog |
- Metabolism of lipids and lipoproteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Lipid digestion, mobilization, and transport
- Signaling by Wnt
- Basigin interactions
- VEGFA-VEGFR2 Pathway
- Cell surface interactions at the vascular wall
- eNOS activation
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Metabolism of nitric oxide
- Signaling by VEGF
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- NOSTRIN mediated eNOS trafficking
- VEGFR2 mediated vascular permeability
- XAV939 inhibits tankyrase, stabilizing AXIN
- eNOS activation and regulation
- Signaling by WNT in cancer
|
- Signaling by the B Cell Receptor (BCR)
- Downstream TCR signaling
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Synthesis of PIPs at the plasma membrane
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- Synthesis of IP3 and IP4 in the cytosol
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Phospholipid metabolism
- PI Metabolism
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Negative regulation of the PI3K/AKT network
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Inositol phosphate metabolism
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- TCR signaling
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
|
|
|
|
CAV1 and HRAS |
caveolin 1, caveolae protein, 22kDa |
Harvey rat sarcoma viral oncogene homolog |
- Metabolism of lipids and lipoproteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Lipid digestion, mobilization, and transport
- Signaling by Wnt
- Basigin interactions
- VEGFA-VEGFR2 Pathway
- Cell surface interactions at the vascular wall
- eNOS activation
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Metabolism of nitric oxide
- Signaling by VEGF
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- NOSTRIN mediated eNOS trafficking
- VEGFR2 mediated vascular permeability
- XAV939 inhibits tankyrase, stabilizing AXIN
- eNOS activation and regulation
- Signaling by WNT in cancer
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- EPH-Ephrin signaling
- SOS-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-2 signaling
- Interleukin-3, 5 and GM-CSF signaling
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Adaptive Immune System
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Post NMDA receptor activation events
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- IRS-related events
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- SHC1 events in EGFR signaling
- RAF activation
- IRS-mediated signalling
- FRS2-mediated cascade
- Activation of RAS in B cells
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- Constitutive Signaling by EGFRvIII
|
|
- Hexane-1,6-Diol
- Trifluoroethanol
- Guanosine-5\'-Triphosphate
- Guanosine-5\'-Diphosphate
- N,N\'-DIMETHYL-N-(ACETYL)-N\'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
|
|
|
CAV1 and EGFR |
caveolin 1, caveolae protein, 22kDa |
epidermal growth factor receptor |
- Metabolism of lipids and lipoproteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Lipid digestion, mobilization, and transport
- Signaling by Wnt
- Basigin interactions
- VEGFA-VEGFR2 Pathway
- Cell surface interactions at the vascular wall
- eNOS activation
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Metabolism of nitric oxide
- Signaling by VEGF
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- NOSTRIN mediated eNOS trafficking
- VEGFR2 mediated vascular permeability
- XAV939 inhibits tankyrase, stabilizing AXIN
- eNOS activation and regulation
- Signaling by WNT in cancer
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
RUNX1 and CCND2 |
runt-related transcription factor 1 |
cyclin D2 |
|
- Cyclin D associated events in G1
- G1 Phase
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
|
|
|
|
|
RUNX1 and CTBP2 |
runt-related transcription factor 1 |
C-terminal binding protein 2 |
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by Wnt
- APC truncation mutants are not K63 polyubiquitinated
- repression of WNT target genes
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- truncations of AMER1 destabilize the destruction complex
|
|
|
|
|
CBL and ERBB2 |
Cbl proto-oncogene, E3 ubiquitin protein ligase |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by the B Cell Receptor (BCR)
- Loss of Function of TGFBR2 in Cancer
- Signaling by FGFR in disease
- SMAD2/3 MH2 Domain Mutants in Cancer
- Interleukin-6 signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Regulation of signaling by CBL
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Negative regulation of FGFR signaling
- EGFR downregulation
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Spry regulation of FGF signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by FGFR
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by EGFR in Cancer
- Constitutive Signaling by EGFRvIII
- Interleukin-3, 5 and GM-CSF signaling
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Axon guidance
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Sema4D in semaphorin signaling
- Sema4D induced cell migration and growth-cone collapse
- Innate Immune System
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
|
- Trastuzumab
- Lapatinib
- ado-trastuzumab emtansine
- Pertuzumab
- Afatinib
|
|
|
CBL and SHC1 |
Cbl proto-oncogene, E3 ubiquitin protein ligase |
SHC (Src homology 2 domain containing) transforming protein 1 |
- Signaling by the B Cell Receptor (BCR)
- Loss of Function of TGFBR2 in Cancer
- Signaling by FGFR in disease
- SMAD2/3 MH2 Domain Mutants in Cancer
- Interleukin-6 signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Regulation of signaling by CBL
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Negative regulation of FGFR signaling
- EGFR downregulation
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Spry regulation of FGF signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by FGFR
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by EGFR in Cancer
- Constitutive Signaling by EGFRvIII
- Interleukin-3, 5 and GM-CSF signaling
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
- Signaling by GPCR
- Signaling by EGFRvIII in Cancer
- Platelet Aggregation (Plug Formation)
- SHC1 events in ERBB2 signaling
- IRE1alpha activates chaperones
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- SHC-mediated signalling
- G-protein beta:gamma signalling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- GPCR downstream signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Signalling to ERKs
- IGF1R signaling cascade
- XBP1(S) activates chaperone genes
- G beta:gamma signalling through PI3Kgamma
- Unfolded Protein Response (UPR)
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SHC-mediated signalling
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- SHC-related events
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- SHC1 events in EGFR signaling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Constitutive Signaling by EGFRvIII
- SHC activation
|
|
|
|
|
CBL and EGFR |
Cbl proto-oncogene, E3 ubiquitin protein ligase |
epidermal growth factor receptor |
- Signaling by the B Cell Receptor (BCR)
- Loss of Function of TGFBR2 in Cancer
- Signaling by FGFR in disease
- SMAD2/3 MH2 Domain Mutants in Cancer
- Interleukin-6 signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Regulation of signaling by CBL
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Negative regulation of FGFR signaling
- EGFR downregulation
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Spry regulation of FGF signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by FGFR
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by EGFR in Cancer
- Constitutive Signaling by EGFRvIII
- Interleukin-3, 5 and GM-CSF signaling
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
CBL and CTNNB1 |
Cbl proto-oncogene, E3 ubiquitin protein ligase |
catenin (cadherin-associated protein), beta 1, 88kDa |
- Signaling by the B Cell Receptor (BCR)
- Loss of Function of TGFBR2 in Cancer
- Signaling by FGFR in disease
- SMAD2/3 MH2 Domain Mutants in Cancer
- Interleukin-6 signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Regulation of signaling by CBL
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Negative regulation of FGFR signaling
- EGFR downregulation
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Spry regulation of FGF signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by FGFR
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by EGFR in Cancer
- Constitutive Signaling by EGFRvIII
- Interleukin-3, 5 and GM-CSF signaling
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
CCNA2 and CDKN1A |
cyclin A2 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
- Cellular Senescence
- G2/M Transition
- Orc1 removal from chromatin
- Cyclin E associated events during G1/S transition
- Cyclin A/B1 associated events during G2/M transition
- G1/S Transition
- G2 Phase
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- DNA Damage/Telomere Stress Induced Senescence
- Synthesis of DNA
- Regulation of DNA replication
- G0 and Early G1
- Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Senescence-Associated Secretory Phenotype (SASP)
- Regulation of APC/C activators between G1/S and early anaphase
- S Phase
- APC/C-mediated degradation of cell cycle proteins
- Cell Cycle, Mitotic
- Orc1 removal from chromatin
- SCF(Skp2)-mediated degradation of p27/p21
- Regulation of mitotic cell cycle
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Mitotic G2-G2/M phases
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- Cyclin E associated events during G1/S transition
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- G1/S Transition
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Signaling by PDGF
- DAP12 interactions
- DNA Damage/Telomere Stress Induced Senescence
- GAB1 signalosome
- Senescence-Associated Secretory Phenotype (SASP)
- S Phase
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- SCF(Skp2)-mediated degradation of p27/p21
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Adaptive Immune System
- PIP3 activates AKT signaling
- Orc1 removal from chromatin
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Transcriptional activation of p53 responsive genes
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Transcriptional activation of cell cycle inhibitor p21
- Signalling by NGF
- Synthesis of DNA
- G1 Phase
- Regulation of DNA replication
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- Signaling by FGFR
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Cell Cycle Checkpoints
|
|
|
|
|
CCNB1 and CDKN1A |
cyclin B1 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
- Phosphorylation of the APC/C
- MASTL Facilitates Mitotic Progression
- Mitotic Prometaphase
- G2/M Checkpoints
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- Activation of NIMA Kinases NEK9, NEK6, NEK7
- Nuclear Envelope Breakdown
- G2/M Transition
- Phosphorylation of Emi1
- Recruitment of NuMA to mitotic centrosomes
- Regulation of PLK1 Activity at G2/M Transition
- M Phase
- Cyclin A/B1 associated events during G2/M transition
- G1/S Transition
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- Mitotic G1-G1/S phases
- Recruitment of mitotic centrosome proteins and complexes
- G2/M DNA replication checkpoint
- Condensation of Prometaphase Chromosomes
- E2F mediated regulation of DNA replication
- G2/M DNA damage checkpoint
- Depolymerisation of the Nuclear Lamina
- Nuclear Pore Complex (NPC) Disassembly
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Regulation of APC/C activators between G1/S and early anaphase
- APC/C-mediated degradation of cell cycle proteins
- Cell Cycle, Mitotic
- APC/C:Cdc20 mediated degradation of Cyclin B
- Resolution of Sister Chromatid Cohesion
- E2F-enabled inhibition of pre-replication complex formation
- Regulation of mitotic cell cycle
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- Cell Cycle Checkpoints
- Centrosome maturation
- Condensation of Prophase Chromosomes
- Mitotic G2-G2/M phases
- Polo-like kinase mediated events
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- Cyclin E associated events during G1/S transition
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- G1/S Transition
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Signaling by PDGF
- DAP12 interactions
- DNA Damage/Telomere Stress Induced Senescence
- GAB1 signalosome
- Senescence-Associated Secretory Phenotype (SASP)
- S Phase
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- SCF(Skp2)-mediated degradation of p27/p21
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Adaptive Immune System
- PIP3 activates AKT signaling
- Orc1 removal from chromatin
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Transcriptional activation of p53 responsive genes
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Transcriptional activation of cell cycle inhibitor p21
- Signalling by NGF
- Synthesis of DNA
- G1 Phase
- Regulation of DNA replication
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- Signaling by FGFR
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Cell Cycle Checkpoints
|
|
|
|
|
CCNB1 and TGFBR2 |
cyclin B1 |
transforming growth factor, beta receptor II (70/80kDa) |
- Phosphorylation of the APC/C
- MASTL Facilitates Mitotic Progression
- Mitotic Prometaphase
- G2/M Checkpoints
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- Activation of NIMA Kinases NEK9, NEK6, NEK7
- Nuclear Envelope Breakdown
- G2/M Transition
- Phosphorylation of Emi1
- Recruitment of NuMA to mitotic centrosomes
- Regulation of PLK1 Activity at G2/M Transition
- M Phase
- Cyclin A/B1 associated events during G2/M transition
- G1/S Transition
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- Mitotic G1-G1/S phases
- Recruitment of mitotic centrosome proteins and complexes
- G2/M DNA replication checkpoint
- Condensation of Prometaphase Chromosomes
- E2F mediated regulation of DNA replication
- G2/M DNA damage checkpoint
- Depolymerisation of the Nuclear Lamina
- Nuclear Pore Complex (NPC) Disassembly
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Regulation of APC/C activators between G1/S and early anaphase
- APC/C-mediated degradation of cell cycle proteins
- Cell Cycle, Mitotic
- APC/C:Cdc20 mediated degradation of Cyclin B
- Resolution of Sister Chromatid Cohesion
- E2F-enabled inhibition of pre-replication complex formation
- Regulation of mitotic cell cycle
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- Cell Cycle Checkpoints
- Centrosome maturation
- Condensation of Prophase Chromosomes
- Mitotic G2-G2/M phases
- Polo-like kinase mediated events
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|